A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma

Clinical Cancer Research

Volumn 21, Issue 7, 2015, Pages 1566-1573

  Galloway, Thomas J ^a   Wirth, Lori J ^b   Colevas, Alexander D ^c   Gilbert, Jill ^d   Bauman, Julie E ^e   Saba, Nabil F ^f   Raben, David ^g   Mehra, Ranee ^a   Ma, Anna W ^h   Atoyan, Ruzanna ^h   Wang, Jing ^h   Burtness, Barbara ^a   Jimeno, Antonio ^g  

^a FOX CHASE CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^h CURIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [4 (3 ETHYLNYLPHENYLAMINO) 7 METHOXYQUINAZOLIN 6 YLOXY] N HYDROXYHEPTANAMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG; 7-(4-(3-ETHYNYLPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)-N-HYDROXYHEPTANAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE; HYDROXAMIC ACID; QUINAZOLINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FAILURE TO THRIVE; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC SYNDROME; HYPERVOLEMIA; HYPOXIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SKIN BIOPSY; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; MIDDLE AGED; PROCEDURES; RADIOTHERAPY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84927782533     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2820     Document Type: Article

References (34)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-301.
3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
4. Gaykalova DA, Mambo E, Choudhary A, Houghton J, Buddavarapu K, Sanford T, et al. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS ONE 2014;9:e93102.
5. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
6. Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol 2013;14:e302-9.
7. Chinnaiyan P, Varambally S, Tomlins SA, Ray S, Huang S, Chinnaiyan AM, et al. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int J Cancer 2006;118:1041-50.
8. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
9. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72.
10. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
12. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-50.
13. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011;29:s5500.
14. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001;12(Suppl 1):S81-7.
15. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-56.
16. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007;29:655-64.
17. Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, et al. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Oral Pathol Med 2011;40:706-14.
18. Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 2006;25:3885-93.
19. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006;5:1967-74.
20. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010;11:459-64.
21. Shi W, Lawrence YR, Choy H, Werner-Wasik M, Andrews DW, Evans JJ, et al. Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. J Neuro Oncol 2014;118:313-9.
22. Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56.
23. Shimizu T, Tolcher AW, LoRusso P, Papadopoulos K, Patnaik A, Smith L, et al. The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer. Eur J Cancer Supp 2010;8:15.
24. Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, et al. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin Cancer Res 2014;20:5032-40.
25. Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011;22:1071-7.
26. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18:2336-43.
27. Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011;105:618-27.
28. Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, et al. Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013;49:1609-18.
29. Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 2014;21:526-33.
30. Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 2013;108:748-54.
31. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Kehlbach R, Rodemann HP. Nuclear epidermal growth factor receptor modulates cellular radio-sensitivity by regulation of chromatin access. Radiother Oncol 2011;99:317-22.
32. Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, et al. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope 2012;122:2762-8.
33. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009;27:2509-15.
34. Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 2014;4:280-91.